Nektar Therapeutics

NASDAQ:NKTR

0.64 (USD) • At close April 17, 2025
Bedrijfsnaam Nektar Therapeutics
Symbool NKTR
Munteenheid USD
Prijs 0.636
Beurswaarde 118,436,586
Dividendpercentage 0%
52-weken bereik 0.43 - 1.93
Industrie Biotechnology
Sector Healthcare
CEO Mr. Howard W. Robin
Website https://www.nektar.com

An error occurred while fetching data.

Over Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder

Vergelijkbare Aandelen

Codexis, Inc. logo

Codexis, Inc.

CDXS

2.11 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

10.79 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

6.33 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

2.16 USD

Merus N.V. logo

Merus N.V.

MRUS

43.055 USD

Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

VERV

4.59 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

5.99 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)